NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease
Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…Characterisation of the Pattern of Daily Motor Fluctuations in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study
Objective: To characterise the pattern of daily motor fluctuations in Korean patients with Parkinson’s disease (PD) and early motor fluctuations. Background: Patients with PD may…Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.
Objective: To investigate the efficacy of botulinum toxin injection (BoNTA) in correcting eyebrow asymmetry in patients with hemifacial spasms (HFS). Background: HFS typically affects women…Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias
Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study
Objective: The objectives of this study are to describe the prevalence of different motor phenotypes (MP) in a cohort of Parkinson’s Disease (PD) patients, to…A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler
Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…Effects of Mental Practice on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial
Objective: To compare the effects of an experimental intervention (EI) based on NCI with a control intervention (CI) of equal volume and intensity, differing only…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease
Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…
- « Previous Page
- 1
- …
- 402
- 403
- 404
- 405
- 406
- …
- 1942
- Next Page »